


PHARMACEUTICAL 2021

Stoke Therapeutics Inc. Rank 77 of 409







RealRate

PHARMACEUTICAL 2021

Stoke Therapeutics Inc. Rank 77 of 409

The relative strengths and weaknesses of Stoke Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Stoke Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 256% points. The greatest weakness of Stoke Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 66%, being 421% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	293,930
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,425
Liabilities, Non-Current	422
Other Assets	1,320
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	801
Property and Equipment	2,675
Research and Development	32,197
Revenues	0
Selling, General and Administrative Expense	20,847

Output Variable	Value in 1000 USD
Assets	297,925
Liabilities	11,847
Expenses	53,044
Stockholders Equity	286,078
Net Income	-52,243
Comprehensive Net Income	-52,243
Economic Capital Ratio	66%

